• Something wrong with this record ?

Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

JN. Eckardt, S. Stasik, C. Röllig, T. Sauer, S. Scholl, A. Hochhaus, M. Crysandt, TH. Brümmendorf, R. Naumann, B. Steffen, V. Kunzmann, H. Einsele, M. Schaich, A. Burchert, A. Neubauer, K. Schäfer-Eckart, C. Schliemann, SW. Krause, R. Herbst, M....

. 2023 ; 13 (1) : 18. [pub] 20230124

Language English Country United States

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc23004524

Functional perturbations of the cohesin complex with subsequent changes in chromatin structure and replication are reported in a multitude of cancers including acute myeloid leukemia (AML). Mutations of its STAG2 subunit may predict unfavorable risk as recognized by the 2022 European Leukemia Net recommendations, but the underlying evidence is limited by small sample sizes and conflicting observations regarding clinical outcomes, as well as scarce information on other cohesion complex subunits. We retrospectively analyzed data from a multi-center cohort of 1615 intensively treated AML patients and identified distinct co-mutational patters for mutations of STAG2, which were associated with normal karyotypes (NK) and concomitant mutations in IDH2, RUNX1, BCOR, ASXL1, and SRSF2. Mutated RAD21 was associated with NK, mutated EZH2, KRAS, CBL, and NPM1. Patients harboring mutated STAG2 were older and presented with decreased white blood cell, bone marrow and peripheral blood blast counts. Overall, neither mutated STAG2, RAD21, SMC1A nor SMC3 displayed any significant, independent effect on clinical outcomes defined as complete remission, event-free, relapse-free or overall survival. However, we found almost complete mutual exclusivity of genetic alterations of individual cohesin subunits. This mutual exclusivity may be the basis for therapeutic strategies via synthetic lethality in cohesin mutated AML.

Department of Hematology Oncology and Immunology Philipps University Marburg Marburg Germany

Department of Hematology Oncology and Palliative Care Rems Murr Hospital Winnenden Winnenden Germany

Department of Hematology Oncology and Palliative Care Robert Bosch Hospital Stuttgart Germany

Department of Hematology Oncology Hemostaseology and Cell Therapy University Hospital RWTH Aachen Aachen Germany

Department of Hematology University Hospital Essen Essen Germany

Department of Internal Medicine 1 University Hospital Carl Gustav Carus Dresden Germany

Department of Internal Medicine 2 Jena University Hospital Jena Germany

Department of Internal Medicine 5 Paracelsus Medizinische Privatuniversität and University Hospital Nurnberg Nurnberg Germany

Department of Internal Medicine Hematology and Oncology Masaryk University Hospital Brno Czech Republic

Department of Internal Medicine University Hospital Kiel Kiel Germany

Department of Medicine A University Hospital Münster Münster Germany

Department of Neurology University Hospital Carl Gustav Carus Technische Universität Dresden Dresden Germany

Division of Health Care Sciences Dresden International University Dresden Germany

DKMS Clinical Trials Unit Dresden Germany

German Cancer Research Center and Medical Clinic 5 University Hospital Heidelberg Heidelberg Germany

German Consortium for Translational Cancer Research DKTK Heidelberg Germany

Medical Clinic 1 Hematology and Celltherapy University Hospital Leipzig Leipzig Germany

Medical Clinic 2 St Bernward Hospital Hildesheim Germany

Medical Clinic 2 University Hospital Frankfurt Frankfurt Germany

Medical Clinic 3 Chemnitz Hospital AG Chemnitz Germany

Medical Clinic 3 St Marien Hospital Siegen Siegen Germany

Medical Clinic 5 University Hospital Erlangen Erlangen Germany

Medical Clinic and Policlinic 2 University Hospital Würzburg Würzburg Germany

National Center for Tumor Disease Dresden Germany

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004524
003      
CZ-PrNML
005      
20230425141449.0
007      
ta
008      
230418s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41408-023-00790-1 $2 doi
035    __
$a (PubMed)36693840
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Eckardt, Jan-Niklas $u Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany. jan-niklas.eckardt@uniklinikum-dresden.de $u Division of Health Care Sciences, Dresden International University, Dresden, Germany. jan-niklas.eckardt@uniklinikum-dresden.de $1 https://orcid.org/0000000236492823
245    10
$a Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome / $c JN. Eckardt, S. Stasik, C. Röllig, T. Sauer, S. Scholl, A. Hochhaus, M. Crysandt, TH. Brümmendorf, R. Naumann, B. Steffen, V. Kunzmann, H. Einsele, M. Schaich, A. Burchert, A. Neubauer, K. Schäfer-Eckart, C. Schliemann, SW. Krause, R. Herbst, M. Hänel, M. Hanoun, U. Kaiser, M. Kaufmann, Z. Rácil, J. Mayer, T. Cerqueira, F. Kroschinsky, WE. Berdel, H. Serve, C. Müller-Tidow, U. Platzbecker, CD. Baldus, J. Schetelig, T. Siepmann, M. Bornhäuser, JM. Middeke, C. Thiede
520    9_
$a Functional perturbations of the cohesin complex with subsequent changes in chromatin structure and replication are reported in a multitude of cancers including acute myeloid leukemia (AML). Mutations of its STAG2 subunit may predict unfavorable risk as recognized by the 2022 European Leukemia Net recommendations, but the underlying evidence is limited by small sample sizes and conflicting observations regarding clinical outcomes, as well as scarce information on other cohesion complex subunits. We retrospectively analyzed data from a multi-center cohort of 1615 intensively treated AML patients and identified distinct co-mutational patters for mutations of STAG2, which were associated with normal karyotypes (NK) and concomitant mutations in IDH2, RUNX1, BCOR, ASXL1, and SRSF2. Mutated RAD21 was associated with NK, mutated EZH2, KRAS, CBL, and NPM1. Patients harboring mutated STAG2 were older and presented with decreased white blood cell, bone marrow and peripheral blood blast counts. Overall, neither mutated STAG2, RAD21, SMC1A nor SMC3 displayed any significant, independent effect on clinical outcomes defined as complete remission, event-free, relapse-free or overall survival. However, we found almost complete mutual exclusivity of genetic alterations of individual cohesin subunits. This mutual exclusivity may be the basis for therapeutic strategies via synthetic lethality in cohesin mutated AML.
650    _2
$a lidé $7 D006801
650    _2
$a chromozomální proteiny, nehistonové $x genetika $7 D002868
650    12
$a akutní myeloidní leukemie $x diagnóza $x genetika $7 D015470
650    _2
$a mutace $7 D009154
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Stasik, Sebastian $u Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany $1 https://orcid.org/0000000302714894
700    1_
$a Röllig, Christoph $u Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany
700    1_
$a Sauer, Tim $u German Cancer Research Center (DKFZ) and Medical Clinic V, University Hospital Heidelberg, Heidelberg, Germany
700    1_
$a Scholl, Sebastian $u Department of Internal Medicine II, Jena University Hospital, Jena, Germany
700    1_
$a Hochhaus, Andreas $u Department of Internal Medicine II, Jena University Hospital, Jena, Germany
700    1_
$a Crysandt, Martina $u Department of Hematology, Oncology, Hemostaseology, and Cell Therapy, University Hospital RWTH Aachen, Aachen, Germany
700    1_
$a Brümmendorf, Tim H $u Department of Hematology, Oncology, Hemostaseology, and Cell Therapy, University Hospital RWTH Aachen, Aachen, Germany $1 https://orcid.org/0000000296773723
700    1_
$a Naumann, Ralph $u Medical Clinic III, St. Marien-Hospital Siegen, Siegen, Germany
700    1_
$a Steffen, Björn $u Medical Clinic II, University Hospital Frankfurt, Frankfurt (Main), Germany
700    1_
$a Kunzmann, Volker $u Medical Clinic and Policlinic II, University Hospital Würzburg, Würzburg, Germany
700    1_
$a Einsele, Hermann $u Medical Clinic and Policlinic II, University Hospital Würzburg, Würzburg, Germany
700    1_
$a Schaich, Markus $u Department of Hematology, Oncology and Palliative Care, Rems-Murr-Hospital Winnenden, Winnenden, Germany
700    1_
$a Burchert, Andreas $u Department of Hematology, Oncology and Immunology, Philipps-University-Marburg, Marburg, Germany $1 https://orcid.org/0000000284118844
700    1_
$a Neubauer, Andreas $u Department of Hematology, Oncology and Immunology, Philipps-University-Marburg, Marburg, Germany
700    1_
$a Schäfer-Eckart, Kerstin $u Department of Internal Medicine V, Paracelsus Medizinische Privatuniversität and University Hospital Nurnberg, Nurnberg, Germany
700    1_
$a Schliemann, Christoph $u Department of Medicine A, University Hospital Münster, Münster, Germany $1 https://orcid.org/0000000317559583
700    1_
$a Krause, Stefan W $u Medical Clinic V, University Hospital Erlangen, Erlangen, Germany $1 https://orcid.org/0000000252594651
700    1_
$a Herbst, Regina $u Medical Clinic III, Chemnitz Hospital AG, Chemnitz, Germany
700    1_
$a Hänel, Mathias $u Medical Clinic III, Chemnitz Hospital AG, Chemnitz, Germany
700    1_
$a Hanoun, Maher $u Department of Hematology, University Hospital Essen, Essen, Germany $1 https://orcid.org/0000000217548940
700    1_
$a Kaiser, Ulrich $u Medical Clinic II, St. Bernward Hospital, Hildesheim, Germany
700    1_
$a Kaufmann, Martin $u Department of Hematology, Oncology and Palliative Care, Robert-Bosch-Hospital, Stuttgart, Germany
700    1_
$a Rácil, Zdenek $u Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital, Brno, Czech Republic
700    1_
$a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, Masaryk University Hospital, Brno, Czech Republic
700    1_
$a Cerqueira, Tiago $u Division of Health Care Sciences, Dresden International University, Dresden, Germany
700    1_
$a Kroschinsky, Frank $u Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany $1 https://orcid.org/0000000242357580
700    1_
$a Berdel, Wolfgang E $u Department of Medicine A, University Hospital Münster, Münster, Germany
700    1_
$a Serve, Hubert $u Medical Clinic II, University Hospital Frankfurt, Frankfurt (Main), Germany
700    1_
$a Müller-Tidow, Carsten $u German Cancer Research Center (DKFZ) and Medical Clinic V, University Hospital Heidelberg, Heidelberg, Germany
700    1_
$a Platzbecker, Uwe $u Medical Clinic I Hematology and Celltherapy, University Hospital Leipzig, Leipzig, Germany
700    1_
$a Baldus, Claudia D $u Department of Internal Medicine, University Hospital Kiel, Kiel, Germany $1 https://orcid.org/000000020748834X
700    1_
$a Schetelig, Johannes $u Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany $u DKMS Clinical Trials Unit, Dresden, Germany $1 https://orcid.org/0000000227802981
700    1_
$a Siepmann, Timo $u Division of Health Care Sciences, Dresden International University, Dresden, Germany $u Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
700    1_
$a Bornhäuser, Martin $u Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany $u German Consortium for Translational Cancer Research DKTK, Heidelberg, Germany $u National Center for Tumor Disease (NCT), Dresden, Germany
700    1_
$a Middeke, Jan Moritz $u Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany $1 https://orcid.org/000000033250293X
700    1_
$a Thiede, Christian $u Department of Internal Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany $1 https://orcid.org/0000000312412048
773    0_
$w MED00187996 $t Blood cancer journal $x 2044-5385 $g Roč. 13, č. 1 (2023), s. 18
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36693840 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141446 $b ABA008
999    __
$a ok $b bmc $g 1924928 $s 1190733
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 13 $c 1 $d 18 $e 20230124 $i 2044-5385 $m Blood cancer journal $n Blood Cancer J $x MED00187996
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options